Once Pfizer Inc. completes its acquisition of Wyeth, its smaller U. S. rival valued at $68-million, Martin Mackay, Pfizer's current head of research confirmed in an interview, there will be two research chiefs, one in charge of traditional medicines and the other of biotech drugs and vaccines.